Assessment the of Interleukin-6 Level and Gene Polymorphism (rs1800795) at the Risk for Colorectal Cancer Patients

Abstract

During tumor development, proinflammatory cytokines have critical role. Interleukin -6 is pleotropic cytokine that play crucial role in inflammation, immune regulation and tumorigenesis by activating multiple carcinogenic pathways. This study aimed to demonstrate an associated between IL-6 polymorphism (rs1800795) and circulating level of IL-6 with colorectal cancer in Iraq patients.  Fifty blood samples were collected from both colorectal cancer patients and healthy individuals. The level of IL-6 in the serum of the study groups was determined using a specific sandwich enzyme-linked immunosorbent test (ELISA). While, the (rs1800795) polymorphisms was screened by using DNA- Sequencing technology.  In the present study results revealed that the body mass index and IL-6 were significant higher in patients group compared with control group, (P-value = 0.0371 and 0.0006, respectively). Analysis of the IL-6 -174G/C polymorphism revealed that both in the patient and control groups, persons with the G allele had considerably higher serum levels of IL-6 than those with the C allele. (25.13 ± 1.35 versus 19. 81 ± 0.98, P- value= 0.0093) and (16.42 ± 0.3 versus 11.46 ± 0.89, P- value= 0.0016), respectively. It was concluded IL-6 - 174G allele could be used as prognostic biomarker for colorectal cancer in Iraqi patients. Thereby, several therapeutics targeting IL-6 may be used as promising opportunity in the treatment of colorectal cancer.